Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:02 AM
Ignite Modification Date:
2025-12-25 @ 4:02 AM
NCT ID:
NCT00130702
Eligibility Criteria:
Inclusion Criteria:
* Patients must have pathologically documented acute myelogenous leukemia and either not be a candidate for myelosuppressive chemotherapy due to age or comorbid disease; or have relapsed acute myelogenous leukemia or be refractory to standard therapy and not likely to require cytoreductive therapy within 30 days.
* ECOG performance status 0, 1 or 2
* Age \> 18 years
* Adequate kidney and hepatic function
* Greater than 4 weeks from any chemotherapy, radiotherapy, immunotherapy, or systemic steroid therapy with the exception of hydroxyurea.
* Greater than 2 months following bone marrow or peripheral blood stem cell transplantation or donor lymphocyte infusion.
Exclusion Criteria:
* Uncontrolled active infection
* Urgent need for cytoreductive chemotherapy, surgery, or radiotherapy
* Current chemotherapy or chemotherapy within the last 4 weeks.
* Pregnancy or nursing mothers
* Infection with HIV
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00130702
Study Brief:
Protocol Section:
NCT00130702